Results 31 to 40 of about 1,329,719 (361)
European Journal of Medical Research, 2023 In the new century, cardiac amyloidosis has received more attention from many countries and institutions, leading to innovations in the essence of the pathology, biological markers, noninvasive tests, and staging diagnoses and treatments for this disease.
Zhenyue Fu +8 more
semanticscholar +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background Outcomes data in patients with cardiac amyloidosis after implantable cardioverter‐defibrillator (ICD) implantation are limited. We compared outcomes of patients with ICDs implanted for cardiac amyloidosis versus nonischemic cardiomyopathies ...
Angela Y. Higgins +9 more
doaj +1 more source
European Journal of Heart Failure, 2021 Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions ...
P. García-Pavía +23 more
semanticscholar +1 more source
European Journal of Heart Failure, 2022 An algorithm for non‐invasive diagnosis of amyloid transthyretin cardiac amyloidosis (ATTR‐CA) and novel disease‐modifying therapies have prompted an active search for CA. We examined the prevalence of CA in different settings based on literature data.
A. Aimo +8 more
semanticscholar +1 more source
Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis
Methodist DeBakey Cardiovascular Journal, 2022 Cardiac amyloidosis is increasingly recognized as an underlying cause of left ventricular wall thickening, heart failure, and arrhythmia with variable clinical presentation.
Sajan S. Gill +4 more
doaj +1 more source
Conventional heart failure therapy in cardiac ATTR amyloidosis
European Heart Journal, 2023 Aims The aims of this study were to assess prescription patterns, dosages, discontinuation rates, and association with prognosis of conventional heart failure medications in patients with transthyretin cardiac amyloidosis (ATTR-CA). Methods and results A
A. Ioannou +28 more
semanticscholar +1 more source
ESC Heart Failure, 2021 Aims The aim of this study was to examine the prevalence of amyloid transthyretin (ATTR) cardiac amyloidosis in patients 1–2 years after trans‐catheter aortic valve replacement (TAVR) and to assess their clinical and echocardiographic outcome and long ...
Sara Shimoni +9 more
doaj +1 more source
Abnormal Myocardial Blood Flow Reserve Observed in Cardiac Amyloidosis [PDF]
, 2016 We performed real-time myocardial contrast echocardiography on a patient with cardiac amyloidosis and previous normal coronary angiography presenting with atypical chest pain to assess myocardial blood flow reserve (MBFR).
Greaves, K, Nam, MC, Nel, K, Senior, R
core +1 more source
The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa [PDF]
, 2016 Transthyretin (TTR) pV142I (rs76992529-A) is one of the 113 variants in the human TTR gene associated with systemic amyloidosis. It results from a G to A transition at a CG dinucleotide in the codon for amino acid 122 of the mature protein (TTR V122I ...
Alexander, Alice A +10 more
core +1 more source
European Journal of Heart Failure, 2022 The incidence and risk factors of pacemaker (PM) implantation in patients with cardiac amyloidosis (CA) are largely unexplored. We sought to characterize the trends in the incidence of permanent PM and to identify baseline predictors of future PM ...
A. Porcari +23 more
semanticscholar +1 more source